10-Q: Apollo Commercial Swings to Profit in Q3 2025

Sentiment:

Quarterly Report


Apollo Commercial Real Estate Finance, Inc. reported a significant turnaround, posting net income available to common stockholders of $47.7 million, or $0.34 per diluted share, for Q3 2025, compared to a net loss in the prior year.

Capital raiseThe company may seek to raise further equity or debt capital in the future to fund new investments or refinance expiring indebtedness.During the nine months ended September 30, 2025, the company entered into two new secured credit facilities with Morgan Stanley and new facilities with Atlas and Barclays, collectively providing $1.4 billion of additional borrowing capacity.Capacity was increased under existing secured credit facilities with JPMorgan ($500.0 million), Barclays ($100.0 million), Barclays Private Securitization ($283.5 million), and the Revolving Credit Facility ($115.0 million).The company refinanced its existing 2026 and 2028 Term Loans with a new $750.0 million 2030 Term Loan.
Better than expectedNet income available to common stockholders for Q3 2025 was $47.7 million, a significant improvement from a net loss of $94.6 million in Q3 2024.Net income available to common stockholders for the nine months ended September 30, 2025, was $88.3 million, compared to a net loss of $169.5 million in the same period last year.Net realized loss on investments was significantly lower at $7.4 million for 9M 2025 compared to $128.2 million for 9M 2024.A $17.4 million gain on litigation settlement contributed positively to income from equity method investment.

Summary

  • Net income available to common stockholders for Q3 2025 was $47.7 million ($0.34 per diluted share), a significant improvement from a net loss of $94.6 million (($0.69) per diluted share) in Q3 2024.
  • For the nine months ended September 30, 2025, net income available to common stockholders was $88.3 million ($0.62 per diluted share), compared to a net loss of $169.5 million (($1.23) per diluted share) in the same period last year.
  • Total assets increased to $9.52 billion as of September 30, 2025, from $8.41 billion at December 31, 2024, driven by an increase in commercial mortgage loans.
  • Commercial mortgage loans, net, grew to $8.15 billion from $6.72 billion, while subordinate loans, net, decreased to $153.8 million from $388.8 million.
  • The company committed $3.1 billion to new loans and provided $701.5 million in add-on fundings during the nine months ended September 30, 2025, while receiving $2.1 billion from loan repayments and sales.
  • The debt-to-equity ratio increased to 3.8 as of September 30, 2025, from 3.2 at December 31, 2024.
  • Unfunded loan commitments stood at $1.0 billion as of September 30, 2025, with $779.4 million expected to be funded in the short term.
  • A $17.4 million gain on litigation settlement related to the Massachusetts Healthcare JV significantly contributed to income from equity method investment in Q3 2025.
  • The weighted-average cash coupon on the loan portfolio decreased to 7.0% from 7.5% year-over-year.
  • The company refinanced its existing 2026 and 2028 Term Loans with a new $750 million 2030 Term Loan in June 2025.
  • Subsequent to the quarter, $388.0 million in new commitments were closed, and $271.3 million was received from loan repayments, including a £149.8 million ($199.9 million USD) UK senior housing mortgage.

Sentiment

Score: 7

Explanation: The company demonstrated a strong turnaround in profitability, significantly reducing realized losses and benefiting from a litigation settlement. While net interest income declined and leverage increased, the overall financial performance improved substantially, and the company maintained strong liquidity and compliance with debt covenants. The forward-looking statements indicate continued strategic investment and capital management.

Positives

  • Shift from net loss to significant net income for both the three and nine months ended September 30, 2025.
  • Substantial increase in income from equity method investment, driven by a $17.4 million gain on litigation settlement related to the Massachusetts Healthcare JV.
  • Significantly lower net realized loss on investments ($7.4 million in 9M 2025 vs. $128.2 million in 9M 2024).
  • Decrease in Specific CECL Allowance by $7.5 million in Q3 2025, primarily due to a discounted payoff of the Michigan Office Loan.
  • Successful refinancing of senior secured term loans with a new $750 million 2030 Term Loan, extending maturity to June 2030.
  • Increased borrowing capacity and extended maturities on several secured debt arrangements and the Revolving Credit Facility.
  • Maintained compliance with all debt covenants.
  • Post-quarter-end, closed $388.0 million in new commitments and received $271.3 million in loan repayments, indicating continued investment activity and portfolio liquidity.
  • Risk rating upgrade for a Berlin, Germany office property loan from 4 to 3 following modification.

Negatives

  • Net interest income decreased by $3.0 million in Q3 2025 compared to Q2 2025, and by $32.9 million in 9M 2025 compared to 9M 2024, primarily due to lower average loan balances and lower average index rates.
  • Net loss related to real estate owned operations in Q3 2025, primarily due to hotel seasonality and cessation of expense capitalization for a component of the Brooklyn Multifamily Development.
  • Weighted-average cash coupon on the loan portfolio decreased from 7.5% to 7.0%.
  • Accumulated deficit increased to ($840.2 million) as of September 30, 2025, from ($822.7 million) at December 31, 2024.
  • Total stockholders' equity slightly decreased to $1.86 billion from $1.87 billion.
  • The debt-to-equity ratio increased to 3.8 from 3.2, indicating higher leverage.
  • Foreign currency translation shifted to a loss of ($16.9 million) in Q3 2025 from a gain of $60.1 million in Q3 2024.
  • Common stock dividends declared per share decreased for the nine-month period ($0.75 in 9M 2025 vs $0.95 in 9M 2024).

Risks

  • Credit Risk: Subject to varying degrees of credit risk in connection with target assets, despite efforts to acquire high-quality assets and deploy value-driven underwriting. Unanticipated credit losses could adversely impact operating results.
  • Interest Rate Risk: Highly sensitive to fiscal and monetary policies, economic and political considerations. Mismatches between target assets and borrowings, and changes in prepayment rates, could affect returns.
  • Liquidity Risk: Ability to meet potential cash requirements, including funding commitments, repaying borrowings, and making distributions, is crucial.
  • Prepayment Risk: Principal may be repaid at a different rate than anticipated, causing returns on an asset to be less than expected.
  • Market Risk: Commercial mortgage assets are subject to volatility due to national, regional, and local economic conditions, local real estate conditions, industry slowdowns, construction quality, demographic factors, and natural disasters. Decreases in property values reduce collateral value and potential repayment proceeds.
  • Inflation: While less impactful than interest rates, inflation can still influence performance.
  • Currency Risk: Loans and secured debt arrangements denominated in foreign currencies are subject to fluctuations in currency rates.
  • Macroeconomic Conditions: External events, public health issues, natural disasters, political/economic instability, and macroeconomic trends (inflation, higher interest rates) can adversely impact the global economy and financial markets, making it more difficult to meet debt covenants.
  • REIT Qualification: Must distribute at least 90% of taxable income annually to maintain REIT status, limiting ability to retain earnings and replenish capital.
  • Litigation Risk: Ongoing legal proceedings, such as the AmBase Corporation lawsuit, could result in unquantifiable losses, despite the company's belief that the appeal is without merit.

Future Outlook

The company expects to continue making regular quarterly distributions to common stockholders, aiming to distribute an amount equal to its net taxable income to maintain REIT qualification. It anticipates funding approximately $779.4 million of its $1.0 billion unfunded loan commitments in the short term. The company may seek to raise further equity or debt capital or engage in other forms of borrowings to fund future investments or refinance expiring indebtedness. Management acknowledges potential future challenges from macroeconomic conditions, including higher interest rates, inflation, and market volatility, which could make it more difficult to meet debt covenants.

Management Comments

  • "We believe this strategy will generally keep our credit losses and financing costs low."
  • "We believe this provides us with both cushion and predictability to avoid sudden unexpected outcomes and material repayment requirements."
  • "We were in compliance with our covenants for the periods ended September 30, 2025 and December 31, 2024."
  • "We use leverage for the sole purpose of financing our portfolio and not for the purpose of speculating on changes in interest rates."
  • "We generally intend over time to pay dividends to our stockholders in an amount equal to our net taxable income, if and to the extent authorized by our board of directors."
  • "Distributable Earnings is a key factor considered by the board of directors in setting the dividend and as such we believe Distributable Earnings is useful to investors."
  • "Our Chief Executive Officer and Chief Financial Officer... have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective to give reasonable assurances..."

Industry Context

The commercial real estate finance industry continues to navigate a challenging macroeconomic environment characterized by higher interest rates, inflation, and potential slower economic growth. Apollo Commercial Real Estate Finance, as a REIT, is particularly sensitive to these factors, especially given its portfolio of floating-rate loans and reliance on various debt arrangements. The company's strategy of focusing on institutional quality real estate and active asset management, coupled with hedging strategies for interest rate and currency risks, positions it to mitigate some of these industry-wide pressures. The increase in its debt-to-equity ratio and the decrease in its weighted-average cash coupon reflect the evolving market dynamics and the cost of capital. The company's ability to secure new and extended financing facilities, despite market conditions, suggests continued access to capital, which is crucial in this environment. The gain from a litigation settlement highlights the importance of risk management and legal outcomes in a complex investment landscape.

Comparison to Industry Standards

  • The company's weighted-average origination LTV ratio of 57% (excluding risk-rated "5" loans) is generally considered conservative within the commercial real estate lending industry, suggesting a strong equity cushion from borrowers. This compares favorably to many traditional lenders who might operate with higher LTVs, especially in a volatile market.
  • The increase in the debt-to-equity ratio to 3.8 from 3.2 indicates a higher leverage profile compared to some more conservative REITs, though it is within the range for many commercial mortgage REITs that utilize leverage to enhance returns. For example, some peers might target a debt-to-equity ratio between 2.0 and 4.0, making ARI's current level on the higher end of this typical range.
  • The company's portfolio is 98% floating rate, which is a common strategy for commercial mortgage REITs to benefit from rising interest rates, but also exposes them to interest rate volatility. This is comparable to peers like Starwood Property Trust or Blackstone Mortgage Trust, which also have significant floating-rate exposure.
  • The weighted-average risk rating of 3.0 for the loan portfolio suggests a moderate/average risk profile, which is typical for a diversified commercial real estate debt portfolio. This is a standard internal metric used by many lenders to assess portfolio health.
  • The company's ability to secure $1.4 billion in additional borrowing capacity and extend maturities on various facilities, including the Revolving Credit Facility, demonstrates continued access to institutional capital, which can be a competitive advantage in a tightening credit market. This contrasts with smaller, less established lenders who might face more difficulty in securing or renewing financing.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Equity Incentive Plan AdoptionThe board of directors adopted the Apollo Commercial Real Estate Finance, Inc. 2024 Equity Incentive Plan ("2024 LTIP") on June 17, 2024, following stockholder approval on June 7, 2024. This plan replaces the 2019 LTIP for new awards.2024-06-17Aligns executive and employee incentives with shareholder interests through equity-based compensation, potentially improving long-term performance and retention.
Financial Covenant AmendmentThe company amended its financial covenants effective June 30, 2025, changing the maximum ratio of total indebtedness to tangible net worth from 4.0:1.0 to a ratio of total indebtedness to total assets not to exceed 83.33% (81.82% for the Revolving Credit Facility).2025-06-30Adjusts leverage metrics to potentially provide more flexibility in managing the balance sheet, reflecting current market conditions or strategic objectives. The impact on risk profile depends on the underlying asset quality and market volatility.

Legal Proceedings

  • AmBase Corporation Lawsuit: Plaintiffs filed new motions for leave to appeal to the Court of Appeals on July 12, 2024, which was granted on February 18, 2025. Briefing of the appeal is now complete. The company believes the appeal is without merit, and no reasonable estimate of possible loss can be made.
  • Massachusetts Healthcare Lawsuit: Saint Elizabeth LLC (indirectly owned by a subsidiary of the company and Apollo affiliates) filed a lawsuit against the Commonwealth of Massachusetts on September 4, 2024. A settlement agreement was executed on July 22, 2025, resulting in an additional $44.0 million payment ($18.1 million attributable to ARI) from the Commonwealth. The lawsuit was dismissed with prejudice on August 19, 2025.

Related Party Transactions

  • Management Agreement: The company pays ACREFI Management, LLC (an indirect subsidiary of Apollo Global Management, Inc.) a base management fee of 1.5% per annum of Stockholders' Equity. Fees incurred were $8.6 million (Q3 2025) and $25.6 million (9M 2025).
  • Expense Reimbursements: The company reimbursed the Manager $3.5 million (Q3 2025) and $11.5 million (9M 2025) for certain expenses.
  • Term Loan Refinancing: Apollo Global Funding, LLC (an affiliate of the Manager) served as an arranger for the $750.0 million 2030 Term Loan refinancing, receiving $1.0 million in arrangement fees.
  • Term Loan Investment: Funds managed by an affiliate of the Manager invested $25.0 million in the 2030 Term Loan.
  • Senior Secured Notes: Apollo Global Securities, LLC (an affiliate of the Manager) received $0.4 million in initial purchasers' discounts and commissions for the 2029 Notes issuance in June 2021.
  • Italian Direct Lending Structure: The company formed an Italian closed-end alternative investment fund managed by Apollo Investment Management Europe (Luxembourg) S.A R.L, an affiliate of the Manager. Management fees were de minimis.
  • Atlas Facilities: The Credit Suisse Facility was acquired by Atlas, a wholly-owned investment of a fund managed by an affiliate of the Manager, in February 2023. The company subsequently entered into the Atlas Facility EUR.
  • Massachusetts Healthcare JV: The company, along with Apollo Co-Lenders, formed a joint venture in September 2024, in which the company holds a 41.2% equity interest.

Stakeholder Impact

  • Shareholders: Experienced a significant positive swing in net income and EPS, which could be favorable. However, common stock dividends per share decreased for the nine-month period, and book value per share slightly declined. The ongoing AmBase lawsuit presents an unquantifiable risk.
  • Employees (Manager's): Equity-based compensation expense was recognized, indicating continued incentives.
  • Creditors/Lenders: The company maintained compliance with all debt covenants and successfully refinanced and expanded several debt facilities, suggesting continued creditworthiness. However, the increased debt-to-equity ratio indicates higher leverage.
  • Customers (Borrowers): The company committed substantial new capital to loans and provided add-on fundings, indicating continued support for commercial real estate projects. Loan modifications were also provided to certain borrowers.

Next Steps

  • Continue to monitor developments pertaining to the SEC's climate disclosure rules and evaluate their impact if the stay is lifted.
  • Fund approximately $779.4 million of the $1.0 billion unfunded loan commitments in the short term.
  • Potentially seek to raise further equity or debt capital or engage in other forms of borrowings to fund future investments or refinance expiring indebtedness.
  • Continue to make regular quarterly distributions to common stockholders, aiming to distribute an amount equal to net taxable income.
  • Briefing of the appeal in the AmBase Corporation lawsuit is complete, awaiting further legal developments.

Key Dates

DateDescription
2009-06-29Apollo Commercial Real Estate Finance, Inc. formed in Maryland.
2009-09-29Commenced operations.
2009-12-31Elected to be taxed as a REIT for the taxable year ended December 31, 2009.
2014-03-17Indenture with Wells Fargo Bank, National Association.
2015-09-01Origination date of a Hotel commercial mortgage loan in Manhattan, NY.
2018-06-28AmBase Corporation commenced the Apollo Action lawsuit.
2018-09-01Entered a joint venture with Turner Consulting II, LLC.
2018-10-05Third Supplemental Indenture with Wells Fargo Bank, National Association.
2019-10-23Motion to dismiss AmBase Corporation lawsuit granted.
2019-11-08Court entered judgment dismissing AmBase Corporation complaint.
2020-05-01Origination date of a Residential subordinate loan in Manhattan, NY.
2021-06-15Maturity date of 2029 Notes.
2021-06-29Indenture for 2029 Notes.
2021-07-15Redemption option date for Series B-1 Preferred Stock.
2021-08-01Origination date of a Hotel commercial mortgage loan in Various, US.
2021-10-01Italian closed-end alternative investment fund formed.
2021-11-01Origination date of a Hotel commercial mortgage loan in St. Thomas, USVI.
2021-12-01Origination date of a Residential commercial mortgage loan in Various, UK.
2022-02-01Origination date of an Office commercial mortgage loan in London, UK.
2022-03-01Origination date of an Office commercial mortgage loan in Manhattan, NY.
2022-05-01Origination date of a Retail commercial mortgage loan in Various, US.
2022-08-03Acquired legal title of the Brooklyn Multifamily Development through a deed-in-lieu of foreclosure.
2022-09-01Co-originated Massachusetts Healthcare Loan.
2022-11-01Origination date of an Office commercial mortgage loan in Chicago, IL.
2022-12-01Origination date of an Urban Predevelopment commercial mortgage loan in Miami, FL.
2023-02-01Credit Suisse Facility acquired by Atlas.
2023-03-01Origination date of a Residential commercial mortgage loan in Various, US.
2023-03-31Acquired legal title of the Atlanta Hotel through a deed-in-lieu of foreclosure.
2023-09-01Entered into an interest rate cap for Brooklyn Multifamily Development construction financing.
2023-10-05Appellate Division, First Department granted Apollo's appeal in AmBase Corporation lawsuit.
2023-11-03Plaintiffs filed a motion for leave with the Court of Appeals in AmBase Corporation lawsuit.
2023-12-01Origination date of a Hotel commercial mortgage loan in Various, Europe.
2023-12-01Origination date of a Pubs commercial mortgage loan in Various, UK.
2023-12-15Court dismissed claim against Apollo Global Management, Inc. and the Company in April 2021 Action.
2023-12-31ASU 2023-09 effective for fiscal years beginning after this date.
2024-03-01Atlas Facility USD amended to convert maturity to a two-year initial term.
2024-03-31Atlanta Hotel reclassified to real estate owned, held for investment.
2024-04-01Origination date of a Residential commercial mortgage loan in Emeryville, CA.
2024-04-23Court of Appeals denied Plaintiffs' motion for leave in AmBase Corporation lawsuit.
2024-05-06Registration Statement on Form S-3 filed with the SEC.
2024-06-01Obtained a $73.7 million mortgage secured by the D.C. Hotel.
2024-06-01Origination date of a Hotel commercial mortgage loan in St. Petersburg, FL.
2024-06-01Origination date of a Hotel commercial mortgage loan in Brooklyn, NY.
2024-06-072024 Equity Incentive Plan approved by stockholders.
2024-06-17Board of directors adopted the 2024 Equity Incentive Plan.
2024-07-01Origination date of a Residential commercial mortgage loan in Various, UK.
2024-07-12Plaintiffs filed new motions for leave to appeal to the Court of Appeals in AmBase Corporation lawsuit.
2024-08-01Origination date of a Residential commercial mortgage loan in Various, UK.
2024-08-01Origination date of an Industrial commercial mortgage loan in Various, UK.
2024-09-01Massachusetts Healthcare JV formed.
2024-09-01Extended interest rate cap for Brooklyn Multifamily Development to October 2025.
2024-09-04Saint Elizabeth LLC filed a lawsuit against the Commonwealth of Massachusetts.
2024-10-01Origination date of a Residential commercial mortgage loan in Various, US.
2024-11-01ASU 2024-03 issued.
2024-11-01Commonwealth of Massachusetts paid $21.9 million ($9.0 million attributable to ARI).
2024-12-01Origination date of a Hotel commercial mortgage loan in Indianapolis, IN.
2024-12-01Origination date of a Hotel commercial mortgage loan in New Orleans, LA.
2024-12-01Origination date of a Retail commercial mortgage loan in London, UK.
2025-01-01ASU 2025-05 applicable for reporting periods beginning after this date.
2025-02-01Origination date of a Residential commercial mortgage loan in Miami, FL.
2025-02-01Board of directors meeting to discuss Manager's performance and fees.
2025-02-18Court of Appeals granted Plaintiffs' motion for leave to appeal in AmBase Corporation lawsuit.
2025-03-01Origination date of a Data Centers commercial mortgage loan in West Jordan, UT.
2025-03-01Sold $24.0 million subordinate loan in Miami, FL.
2025-03-31JPMorgan Facility final maturity extended to March 31, 2030.
2025-03-31Deutsche Bank Facility capacity reduced to $200.0 million and final maturity extended to March 31, 2028.
2025-04-01Origination date of a Residential commercial mortgage loan in Various, US.
2025-04-01Origination date of a Data Centers commercial mortgage loan in Slough, UK.
2025-04-01Origination date of an Industrial commercial mortgage loan in Various, US.
2025-05-01Origination date of a Residential commercial mortgage loan in Manhattan, NY.
2025-05-01Origination date of a Data Centers commercial mortgage loan in Abilene, TX.
2025-05-01Origination date of a Mixed Use commercial mortgage loan in London, UK.
2025-06-01Refinanced 2026 and 2028 Term Loans with $750 million 2030 Term Loan.
2025-06-30Financial covenants amended from debt-to-tangible net worth to total indebtedness to total assets ratio.
2025-07-04H.R. 1 (One Big Beautiful Bill Act) enacted.
2025-07-22Saint Elizabeth LLC and Commonwealth of Massachusetts executed a settlement agreement.
2025-08-01Extended interest rate cap for D.C. Hotel mortgage to September 1, 2026.
2025-08-01Origination date of a Residential commercial mortgage loan in Various, UK.
2025-08-01Origination date of a Hotel commercial mortgage loan in San Diego, CA.
2025-08-01Origination date of an Industrial commercial mortgage loan in Various, Europe.
2025-08-07Revolving Credit Facility extended to August 7, 2028.
2025-08-19Massachusetts Healthcare lawsuit dismissed with prejudice.
2025-09-01Management Agreement automatically renewed for a successive one-year term.
2025-09-01Origination date of a Residential commercial mortgage loan in Charlotte, NC.
2025-09-01Origination date of a Hotel commercial mortgage loan in Manhattan, NY.
2025-09-30End of current reporting period.
2025-10-30Filing date of the 10-Q report.
2026-01-01OBBB Act changes to REIT asset test and QBI deduction become effective.
2026-12-15ASU 2024-03 effective for annual periods starting after this date.
2027-12-15ASU 2024-03 effective for interim periods starting after this date.

Recommendation

buy

The company demonstrated a strong financial turnaround, moving from significant losses to substantial net income and positive EPS. This improvement is driven by reduced realized losses on investments and a notable gain from a litigation settlement. While net interest income saw a slight decline and leverage increased, the company's core business of commercial mortgage lending remains active with significant new commitments and repayments. The successful refinancing and expansion of debt facilities indicate robust access to capital. The current stock price relative to the improved earnings and the company's strategic portfolio management, including a conservative LTV and active risk assessment, suggest a positive outlook. The dividend, while slightly lower for the nine-month period, is expected to continue, making it attractive for income-focused investors. The ongoing AmBase lawsuit is a known risk, but management believes it is without merit.

Keywords

Commercial Real Estate Finance, REIT, Mortgage Loans, Subordinate Loans, SEC Filing, 10-Q, Financial Results, Net Income, EPS, Loan Portfolio, Debt-to-Equity, CECL Allowance, Real Estate Owned, Secured Debt, Interest Rate Risk, Credit Risk, Apollo Global Management, Distributable Earnings, Corporate Governance, Litigation Settlement

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.